Eli Lilly and Co. has stopped development of its basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes following conversations with regulatory authorities and other external experts, and not by any new safety signals, according to the company. In February, Lilly delayed regulatory submission in order to assess the potential effects, if any, of changes in liver fat observed with BIL treatment compared with insulin glargine treatment in the Phase III IMAGINE trial...